CardioPrecision announces entry into the US market with its CoreVista® devices for use in Endoscopic Vessel Harvesting (EVH).

Coincident with the recent investment funding round, CardioPrecision performed first US cases at the prestigious Massachusetts General Hospital, in Boston, using its patented CoreVista® suite of devices.

Reporting from the US, Mr Fraser Sutherland, MD, chief medical officer says “ It’s really fantastic to be in the US at this time. The response to our technology has been remarkable. I really admire the quick pace and ‘can do‘ approach across all stakeholders at MGH that has characterised execution of this important next milestone in our business plan.”

CardioPrecision Ltd, a medical technology company for the treatment of structural heart disease and cardiothoracic interventions, launched its products for EVH in the UK last year. This new clinical application was developed against the unprecedented challenges faced during the COVID pandemic. The devices are used to facilitate endoscopic harvest of the radial artery or long saphenous vein during coronary artery bypass grafting (CABG) procedures, the most commonly performed heart surgery. The company aims to gain momentum in the rapidly growing EVH market with its unique product offering that facilitates faster and more accurate execution of motor tasks during surgery.






About CardioPrecision Ltd

CardioPrecision, based in Glasgow UK, is the global leader in transcervical access for the treatment of structural heart disease and cardiothoracic interventions.  CardioPrecision is dedicated to making patients’ lives better through the development of innovative, less invasive access solutions for cardiothoracic surgery and cardiovascular interventions.  For more information, visit

About Massachusetts General Hospital

MGH is the third oldest general hospital in the United States and is the largest teaching hospital of Harvard Medical School. MHG is consistently ranked among the top five hospitals nationwide in the US, and renowned as one of the best hospitals for cardiac surgery worldwide. Visit


This news release includes forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding expected product benefits, anticipated product approvals, future plans related to the product lines, the benefits of the transaction, including future financial and operating results, objectives and expectations and other statements that are not historical facts. Such statements are based on the views and assumptions of the management of the company and are subject to significant risks and uncertainties.  

Actual future events or results may differ materially from these statements as a result of various factors, including: unexpected costs of device development and approvals, unanticipated outcomes after more expanded pre-clinical and clinical experience with the devices, unexpected changes or delays related to product supply, potentials for unexpected regulatory or quality delays or developments, competitive dynamics, global economic conditions and customer acceptance, and other economic, business, and/or competitive factors. The forward-looking statements speak only as of the date of this communication. Except as required by law, The Company undertakes no obligation to update these statements.


CoreVista is a trademark of CardioPrecision Ltd.